Concepedia

Ivelina Gueorguieva

IG

Statistics

Publications

59

Citations

3.8K

H-Index

33

Active since

2002

Affiliations

Eli Lilly (United States)(Current)

Eli Lilly (United Kingdom)

University of Manchester

Vall d'Hebron Hospital Universitari

Hospital Universitario 12 De Octubre

Ivelina Gueorguieva is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and oncology.

ORCID

Publications per year

2002–2025

59

Publications

59

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla et al. · British Journal of Cancer · 2018 · 274 citations · Full text

, , +13

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2016 · 271 citations · Full text

, , +17

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Robin Kate Kelley, Edward Gane, Eric Assénat et al. · Clinical and Translational Gastroenterology · 2019 · 245 citations · Full text

, , +17

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Jordi Rodón, Michael A. Carducci, Juan Manuel Sepúlveda-Sánchez et al. · Clinical Cancer Research · 2014 · 232 citations

, , +13

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Davide Melisi, Do‐Youn Oh, Antoine Hollebecque et al. · Journal for ImmunoTherapy of Cancer · 2021 · 196 citations · Full text

, , +17

1–5 of 59